EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

Laura Ondrisova, Vaclav Seda, Krystof Hlavac, Petra Pavelkova, Eva Hoferkova, Giorgia Chiodin, Lenka Kostalova, Gabriela Mladonicka Pavlasova, Daniel Filip, Josef Vecera, Pedro Faria Zeni, Jan Oppelt und 19 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci173770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Laura Ondrisova und 30 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine, CEITEC Masaryk University, Brno, Czechia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines, Forkhead Box Protein O1. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL cells’ survival during BTK inhibitor–induced lymphocytosis and/or playing a role in therapy resistance. We show that in approximately 70% of CLL cases, ibrutinib treatment in vivo increases Akt activity above pretherapy levels within several weeks, leading to compensatory CLL cell survival and a more prominent lymphocytosis on therapy. Ibrutinib-induced Akt phosphorylation (pAkt S473 ) is caused by the upregulation of Forkhead box protein O1 (FoxO1) transcription factor, which induces expression of Rictor , an assembly protein for the mTORC2 protein complex that directly phosphorylates Akt at serine 473 (S473). Knockout or inhibition of FoxO1 or Rictor led to a dramatic decrease in Akt phosphorylation and growth disadvantage for malignant B cells in the presence of ibrutinib (or PI3K inhibitor idelalisib) in vitro and in vivo. The FoxO1/Rictor/pAkt S473 axis represents an early nongenetic adaptation to B cell receptor (BCR) inhibitor therapy not requiring PI3Kδ or BTK kinase activity. We further demonstrate that FoxO1 can be targeted therapeutically and its inhibition induces CLL cells’ apoptosis alone or in combination with BTK inhibitors (ibrutinib, acalabrutinib, pirtobrutinib) and blocks their proliferation triggered by T cell factors (CD40L, IL-4, and IL-21).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAdeninePiperidinesForkhead Box Protein O1PyrimidinesProto-Oncogene Proteins c-aktPyrazolesRapamycin-Insensitive Companion of mTOR ProteinHumansAnimalsMiceAgammaglobulinaemia Tyrosine KinasePhosphorylationNeoplasm ProteinsCell Line, Tumor

Stichwörter der Autor:innen

Drug therapyHematologyLeukemiasOncologySignal transduction

Substanzen

AdenineibrutinibPiperidinesForkhead Box Protein O1FOXO1 protein, humanPyrimidinesProto-Oncogene Proteins c-aktPyrazolesRapamycin-Insensitive Companion of mTOR ProteinAgammaglobulinaemia Tyrosine Kinase

Autor:innen und Institutionen

  • Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.
  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
  • Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia.
  • Fourth Department of Internal Medicine-Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Prague, Czechia.
  • Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czechia.

Förderung

  • NCI NIH HHS
  • Cancer Research UK
  • European Research Council
  • MH CZ-DRO
  • NIH
  • Ministry of Health of the Czech Republic
  • Masaryk University
  • National Institute for Cancer Research

Zitieren

APA

Ondrisova, L., Seda, V., Hlavac, K., Pavelkova, P., Hoferkova, E., Chiodin, G., Kostalova, L., Mladonicka Pavlasova, G., Filip, D., Vecera, J., Zeni, P. F., Oppelt, J., Kahounova, Z., Vichova, R., Soucek, K., Panovska, A., Plevova, K., Pospisilova, S., Simkovic, M., …, & Mraz, M. (2024). FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. Journal of Clinical Investigation. https://doi.org/10.1172/jci173770

Vancouver

Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al. FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. Journal of Clinical Investigation. 2024. doi:10.1172/jci173770

BibTeX
@article{Ondrisova2024,
  author = {Ondrisova, Laura and Seda, Vaclav and Hlavac, Krystof and Pavelkova, Petra and Hoferkova, Eva and Chiodin, Giorgia and Kostalova, Lenka and Mladonicka Pavlasova, Gabriela and Filip, Daniel and Vecera, Josef and Zeni, Pedro Faria and Oppelt, Jan and Kahounova, Zuzana and Vichova, Rachel and Soucek, Karel and Panovska, Anna and Plevova, Karla and Pospisilova, Sarka and Simkovic, Martin and Vrbacky, Filip and Lysak, Daniel and Fernandes, Stacey M and Davids, Matthew S and Maiques-Diaz, Alba and Charalampopoulou, Stella and Martin-Subero, Jose I and Brown, Jennifer R and Doubek, Michael and Forconi, Francesco and Mayer, Jiri and Mraz, Marek},
  title = {FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci173770}
}
Kostenlos starten →